ROYALTY INTEREST ACQUISITION AGREEMENT Dated as of December 28, 2017 by and among ELOBIX AB, as Seller, HEALTHCARE ROYALTY PARTNERS III, L.P., as Buyer and solely for the purposes of Section 5.08, Section 5.09 and Article VIII, ALBIREO PHARMA, INC.,...Royalty Interest Acquisition Agreement • March 27th, 2018 • Albireo Pharma, Inc. • Pharmaceutical preparations • New York
This ROYALTY INTEREST ACQUISITION AGREEMENT is made and entered into as of December 28, 2017 by and among Elobix AB, a limited liability company organized under the laws of Sweden, HealthCare Royalty Partners III, L.P., a limited partnership organized under the laws of the State of Delaware and, solely for the purposes of Section 5.08, Section 5.09 and Article VIII, Albireo Pharma, Inc. a Delaware corporation (the “Agreement”).
THIRD AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • March 27th, 2018 • Albireo Pharma, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT (the “Third Amendment”) to the License Agreement, dated as of April 2, 2012, as amended on January 30, 2015 and April 6, 2016 (the “License Agreement”), by and between Elobix AB (“Elobix”), as transferee of Albireo AB, and EA Pharma Co., Ltd. (formerly known as Ajinomoto Pharmaceuticals Co., Ltd., “EA”) is entered into on December 7, 2017 (the “Amendment Effective Date”). Elobix and EA may each be referred to herein individually as a “Party” and collectively as the “Parties.”
